WEBULL
WebtradeDownload

Should Gilead Sciences (GILD) Reconsider Its Global HIV Case After This PAHO Deal?

Simply Wall St · 2d ago
  • Gilead Sciences (NasdaqGS:GILD) announced a partnership with the Pan American Health Organization to expand access to lenacapavir for HIV prevention.
  • The agreement targets twice yearly lenacapavir access across 14 countries in Latin America and the Caribbean.
  • The PAHO deal creates a regional access pathway that goes beyond Gilead's existing voluntary licensing programs for HIV prevention drugs.
  • This new PAHO partnership on twice yearly lenacapavir is a fresh development that investors may want to weigh against prior insights. Check out 2 warning signs that Gilead Sciences investors should know about.

This focus on long acting HIV prevention is not unique to Gilead Sciences, so it can be useful to compare with peers exposed to similar healthcare trends via 39 healthcare AI stocks.

NasdaqGS:GILD Earnings & Revenue Growth as at Sep 2026
NasdaqGS:GILD Earnings & Revenue Growth as at Sep 2026

Gilead Sciences operates as a large US biopharmaceutical group that develops and commercializes treatments for areas of unmet medical need, and its HIV franchise positions it so that access-focused deals with organizations like PAHO can be central to how its prevention portfolio reaches patients across regions.

3 things going right for Gilead Sciences that this headline doesn't cover.

How The PAHO Lenacapavir Deal Tests The Gilead Sciences Narrative

The Gilead Sciences narrative hinges on HIV remaining a powerful engine while newer drugs and wider access reshape the mix away from older therapies, and this PAHO partnership goes straight at that bet for prevention. It pushes lenacapavir deeper into emerging markets, which is exactly where the story leans on expanded access.

"New product launches and expanded global access are driving revenue growth and improving Gilead's product mix, reducing reliance on legacy drugs..."

See how the full story points towards a $158 fair value for Gilead Sciences.

The PAHO agreement squarely supports the catalyst that analysts already highlight, which is broader access to Yeztugo or lenacapavir in emerging markets to reshape Gilead Sciences’ HIV mix. It gives the prevention story a concrete regional channel and ties into the PURPOSE 2 trial work by turning clinical investment into an access mechanism rather than a one country play.

Pressure lands on a different plank of the thesis. Heavy reliance on HIV was already flagged as a risk, and a high profile PAHO route deepens that exposure if pricing, logistics or reimbursement in Latin America and the Caribbean fall short of expectations. That matters more as rivals such as ViiV Healthcare and Merck chase their own long acting prevention approaches.

For an investor, a clear narrative about HIV access and concentration risk is what turns this PAHO headline from background noise into something that genuinely shapes a Gilead Sciences decision.

The quiet Gilead Sciences number most holders rarely check

Beyond the headlines and trial results, there is a plain cash flow estimate of what Gilead Sciences may be worth that you can line up against today's share price. Find out exactly what Gilead Sciences is worth today based on its cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.